- Home
- GITS vs EVOK Comparison
GITS vs EVOK Comparison
Compare GITS & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- EVOK
- Stock Information
- Founded
- GITS 2018
- EVOK 2007
- Country
- GITS South Korea
- EVOK United States
- Employees
- GITS N/A
- EVOK N/A
- Industry
- GITS
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- EVOK Health Care
- Exchange
- GITS Nasdaq
- EVOK Nasdaq
- Market Cap
- GITS 4.1M
- EVOK 4.2M
- IPO Year
- GITS N/A
- EVOK 2013
- Fundamental
- Price
- GITS $2.56
- EVOK $4.88
- Analyst Decision
- GITS
- EVOK
- Analyst Count
- GITS 0
- EVOK 0
- Target Price
- GITS N/A
- EVOK N/A
- AVG Volume (30 Days)
- GITS 2.4M
- EVOK 7.2M
- Earning Date
- GITS 07-22-2025
- EVOK 08-12-2025
- Dividend Yield
- GITS N/A
- EVOK N/A
- EPS Growth
- GITS N/A
- EVOK N/A
- EPS
- GITS N/A
- EVOK N/A
- Revenue
- GITS N/A
- EVOK $11,594,083.00
- Revenue This Year
- GITS N/A
- EVOK $57.82
- Revenue Next Year
- GITS N/A
- EVOK $59.12
- P/E Ratio
- GITS N/A
- EVOK N/A
- Revenue Growth
- GITS N/A
- EVOK 89.89
- 52 Week Low
- GITS $0.87
- EVOK $1.94
- 52 Week High
- GITS $9.78
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- GITS N/A
- EVOK 59.65
- Support Level
- GITS N/A
- EVOK $5.74
- Resistance Level
- GITS N/A
- EVOK $9.88
- Average True Range (ATR)
- GITS 0.00
- EVOK 0.61
- MACD
- GITS 0.00
- EVOK 0.25
- Stochastic Oscillator
- GITS 0.00
- EVOK 32.25
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.